#Germany #Berlin #Ariceum Therapeutics #CFO Appointment #David Schilansky

David Schilansky Takes on CFO Role at Ariceum Therapeutics

Ariceum Therapeutics, a leading private biotech firm based in Berlin, has officially announced the appointment of David Schilansky as its new Chief Financial Officer (CFO). This strategic move is perceived as a pivotal step in steering the company's growth trajectory in the radiopharmaceutical sector.

As of January 10, 2025, David Schilansky succeeds Rainer Sturm, who played an integral role during his tenure. Schilansky comes with an impressive track record of over 25 years in the pharmaceutical and biotechnology industries. His prior experiences include significant roles that have enabled him to garner extensive expertise in scaling companies and fundraising efforts. Notably, he has been involved in raising funds amounting to over a billion US dollars during his career, with accomplishments on major stock exchanges like Nasdaq and Euronext.

Leadership Insight
Manfred Rüdiger, PhD, the CEO of Ariceum Therapeutics, expressed his enthusiasm upon Schilansky's appointment, highlighting that David’s leadership and experience would be crucial for enhancing the company’s visibility among US investors. Dr. Rüdiger stated, "I am delighted to welcome such a high caliber CFO to Ariceum, with a proven track record in accelerated value creation." He also acknowledged Rainer Sturm's contributions in facilitating a smooth transition to the new CFO.

David Schilansky also shared his excitement about joining the company, describing Ariceum as "one of the most promising biotechs in Europe" with the potential to transform patient care in the field of aggressive cancers. He commented on the promising pipeline of radiopharmaceutical products that Ariceum is developing and emphasized his commitment to working closely with the leadership team to further advance these initiatives.

Recent Developments at Ariceum
Ariceum Therapeutics is currently in the Phase 1b clinical trials for its leading radiopharmaceutical candidate, satoreotide. This candidate shows significant potential for treating various aggressive cancers, including small cell lung cancer, pancreatic cancers, and Merkel Cell Carcinoma. Recently, the company released outstanding preclinical data that supports the efficacy of Ac-225 satoreotide in treating these conditions.
Furthermore, Ariceum is pioneering a clinical trial focusing on ATT001, the first Auger therapy clinical trial targeting recurrent glioblastoma—a brain cancer notorious for lacking effective treatment options.

The company has also scaled up its global supply agreements for essential medical radionuclides, Actinium-225 and Lutetium-177, to further enhance the development of its innovative targeted radiopharmaceutical pipeline.

A Look Ahead
As Schilansky takes the helm as CFO, Ariceum Therapeutics has set its sights on the upcoming J.P. Morgan's 43rd Annual Healthcare Conference scheduled for January 13-16, 2025, in San Francisco. Here, the company aims to connect with potential investors and partners, showcasing its strategic growth plans under the new leadership.

The path ahead looks promising for Ariceum; with the convergence of innovative technology, strategic appointments, and a resolute focus on expanding its clinical pipeline, Ariceum is poised to make significant strides in the biopharmaceutical landscape.

About Ariceum Therapeutics
Founded in 2021, Ariceum Therapeutics is dedicated to developing advanced radiopharmaceutical products that address certain neuroendocrine and other challenging cancers. The company is deeply committed to precision treatments that improve patient outcomes and is actively working to expand its market reach across various regions, including Europe, the UK, and the US.